RAYDIAX secures €7.5 million to push TACT toward the clinic
RAYDIAX has raised €7.5 million to advance its therapy-assistance CT scanner, called TACT, into first-in-human studies and to support progress toward a market launch. The funding is intended to help the company transition from development and preclinical work into early clinical evaluation, a key milestone for imaging technologies designed to be used directly in therapeutic settings.
From development to first-in-human studies
The company said the new capital will be used to initiate first-in-human studies, a step that typically helps validate safety, usability, and clinical performance in real-world workflows. For a therapy-assistance CT system, early clinical data can be critical in demonstrating that imaging quality and operational speed meet the needs of time-sensitive procedures, while also supporting downstream regulatory and commercialization efforts.
Positioning for commercialization
Beyond clinical studies, the financing is expected to support activities that bring TACT closer to launch, including product refinement, manufacturing readiness, and preparation for regulatory submissions. While RAYDIAX did not disclose the expected timeline for first-in-human enrollment or a target launch date in the announcement, the round signals an intent to accelerate the company’s path to market.
The move reflects continued investor interest in imaging tools that can be integrated into therapy workflows, where improved guidance and verification may help clinicians make faster, more informed decisions during treatment. As RAYDIAX enters the clinical stage, upcoming trial results will be closely watched as an indicator of whether TACT can translate its promise into measurable clinical and operational benefits.
Related
